◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Summit Therapeutics PLC (SMMT) EBITDA 2006–TTM

Name: Summit Therapeutics PLC (SMMT) ebitda history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-07-25

Summit Therapeutics PLC annual ebitda for fiscal 2025 was -$1.1 billion, a decrease of 542.3% from -$168 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

SMMT Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
EBITDA	—	($1.1B)	($168M)	($69M)	($52M)	($84M)	($37M)	$16M	$12M	($26M)	($25M)	($20M)	($12M)	($7M)	($4M)	($2M)	($9M)	($5M)	($16M)	($19M)	($6M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SMMT Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
EBITDA	($216M)	($189M)	($219M)	—	($232M)	($49M)	($49M)	($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

JAZZ EBITDA — Jazz Pharmaceuticals PLC
ASND EBITDA — Ascendis Pharma AS
EXEL EBITDA — Exelixis Inc
BBIO EBITDA — BridgeBio Pharma Inc
HALO EBITDA — Halozyme Therapeutics Inc
BMRN EBITDA — Biomarin Pharmaceutical Inc

More SMMT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All SMMT financial statements → Interactive SMMT charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.